ArticleAmerican journal of translational research2025
Efficacy and adverse reactions of remimazolam and propofol in patients undergoing gastrointestinal endoscopy: a systematic review and meta-analysis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sedation in Gastrointestinal Endoscopy: From Drug-Centered Protocols to Personalized, Technology-Supported Pathways: A Narrative Review.Journal of clinical medicine · 2026Review
- Remimazolam-based precision anesthesia management combined with nasopharyngeal airway in gastroscopic surgery for a patient with obesity and difficult airway: a successful case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal (GI) endoscopy is crucial for detecting suspicious gastric lesions, screening for gastric cancer, and providing early diagnosis. With an aging population, an increasing number of elderly individuals require gastrointestinal endoscopy.
methodsFour databases were searched to acquire controlled clinical trials on the effects of remimazolam and propofol in patients undergoing GI endoscopy. A meticulous evaluation of the literature quality and data was then performed using Stata software.
resultsSeventeen studies reported significantly lower respiratory depression in the experimental group compared to the control group (odds ratio: OR 0.28; 95% confidence interval (CI): 0.18-0.45; P<0.01). Injection pain (OR: 0.11; 95% CI: 0.06-0.20; P<0.01), hypotension (OR: 0.41; 95% CI: 0.33-0.52; P<0.01), and hypoxemia (OR: 0.38; 95% CI: 0.22-0.63; P<0.01) were also significantly lower in the experimental group. However, propofol was associated with improved sedation success (OR: 0.99; 95% CI: 0.98-1.00; P=0.048) and longer sedation time (SMD: 24.19; 95% CI: 14.60-33.79; P<0.01). Recovery time showed no significant difference between groups (SMD: -0.27; 95% CI: -1.46-0.92; P=0.657).
conclusionThis study suggests that both remimazolam and propofol are efficacious in patients undergoing gastrointestinal endoscopy. Remimazolam significantly reduces complications such as respiratory depression, injection pain, hypotension, and hypoxemia. However, propofol has advantages in improving sedation success and sedation time. These findings are supported by high-quality randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.